News

Sarepta drops as report suggests FDA needs new trials for Elevidys

Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...
BioSpace6d

Lack of Transparency Tarnishes Sarepta’s Sheen as Patient Deaths Trigger FDA Battle

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, ...
BioPharma Dive6d

Sarepta stops Elevidys shipments after standoff with FDA

Company CEO Doug Ingram said the pause was necessary for Sarepta to maintain a "productive and positive working relationship" ...
MM&M6d

Lola Offenback, Author at MM+M - Medical Marketing and Media

Sarepta Therapeutics defies the FDA’s request to stop all shipments of Elevidys; Biogen plops down $2B investment in NC; George Tidmarsh becomes FDA director of CDER.